Stock BFRI BIOFRONTERA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Biofrontera Inc.

Equities

BFRI

US09077D2099

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-26 EDT 		5-day change 1st Jan Change
0.91 USD -4.21% Intraday chart for Biofrontera Inc. -9.00% -67.15%
06-24 Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp CI
05-16 Transcript : Biofrontera Inc., Q1 2024 Earnings Call, May 16, 2024

Business Summary

Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Number of employees: 84

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical Products
100.0 %
29 100.0 % 34 100.0 % +18.82%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
29 100.0 % 34 100.0 % +18.82%

Managers

Managers TitleAgeSince
Hermann Lübbert CEO
 Chief Executive Officer 68 15-02-28
Fred Leffler DFI
 Director of Finance/CFO 40 22-10-23
Erica Gates DFI
 Director of Finance/CFO - 19-07-31
Jon Lyons CTO
 Chief Tech/Sci/R&D Officer - 21-09-30
Alycia Torres ADM
 Chief Administrative Officer - 22-09-30
Daniel Hakansson CMP
 Compliance Officer - 18-12-31
Samantha Widdicombe
- -
Mark Baldyga SAM
 Sales & Marketing - 16-04-30

Members of the board

Members of the board TitleAgeSince
John Borer BRD
 Director/Board Member 66 21-11-01
Hermann Lübbert CEO
 Chief Executive Officer 68 15-02-28
Kevin Weber BRD
 Director/Board Member 66 22-03-01
Heikki Lanckriet BRD
 Director/Board Member 46 23-07-11
Beth Hoffman BRD
 Director/Board Member 67 15-03-02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,089,413 3,590,857 ( 70.56 %) 0 70.56 %

Shareholders

NameEquities%Valuation
Rosalind Advisors, Inc.
9.908 %
504,261 9.908 % 519 389 $
Rosalind Advisors, Inc.
9.908 %
504,261 9.908 % 519 389 $
Laurence Lytton
9.906 %
504,168 9.906 % 519 293 $
The Hewlett Fund LP
9.906 %
504,168 9.906 % 519 293 $
Michael Bigger
9.878 %
502,754 9.878 % 517 837 $
AIGH Capital Management LLC
9.852 %
501,434 9.852 % 516 477 $
AIGH Capital Management LLC
9.852 %
501,434 9.852 % 516 477 $
BIOFRONTERA AG
7.859 %
400,000 7.859 % 412 000 $
Matejka & Partner Asset Management GmbH
1.254 %
63,799 1.254 % 65 713 $
Scotia Capital, Inc.
0.7859 %
40,000 0.7859 % 41 200 $
NameEquities%Valuation
Bard Associates, Inc.
-
183,900 - 11 034 $
G1 Execution Services LLC
-
16,962 - 1 018 $
Clear Street LLC
-
10,689 - 641 $
Citadel Securities GP LLC
-
10,667 - 640 $
Osaic Wealth, Inc.
-
3,352 - 201 $
UBS Securities LLC
-
2,604 - 156 $
U.S. Bank Main Branch (363657)
-
1,000 - 60 $

Holdings

NameEquities%Valuation
BIOFRONTERA AG
8.58%
 521,430 8.58% 1,734,985 $

Company contact information

Biofrontera, Inc.

120 Presidnetial Way Suite 330

01801, Woburn

+781-245-1325

http://www.biofrontera-us.com
address Biofrontera Inc.(BFRI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Ratings for Biofrontera Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.91 USD
Average target price
16 USD
Spread / Average Target
+1,658.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BIOFRONTERA INC. Stock Biofrontera Inc.
-67.15% 4.63M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.61% 811B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.76% 640B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.62% 333B
ABBVIE INC. Stock AbbVie Inc.
+10.44% 302B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.00% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+2.62% 225B
NOVARTIS AG Stock Novartis AG
+12.78% 218B
AMGEN INC. Stock Amgen Inc.
+8.61% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BFRI Stock
  4. Company Biofrontera Inc.